Skip to main content
IMUGENE LIMITED logo

IMUGENE LIMITED — Investor Relations & Filings

Ticker · IMU ISIN · AU000000IMU9 LEI · 984500A5C9KF08EAF248 ASX Professional, scientific and technical activities
Open in API
Filings indexed 1,444 across all filing types
Latest filing 2013-08-13 Interim / Quarterly Rep…
Country AU Australia
Listing ASX IMU

About IMUGENE LIMITED

https://imugene.com

Imugene Limited is a clinical-stage immuno-oncology company focused on developing immunotherapies to activate the immune system against various cancers. The company’s pipeline features multiple platform technologies, including B-cell activating immunotherapies, oncolytic viruses, and CAR-T cell enhancement therapies. Key clinical candidates include HER-Vaxx, targeting HER2-positive gastric cancer, and PD1-Vaxx, a checkpoint inhibitor immunotherapy. Imugene is also advancing the CF33 oncolytic virus platform, which includes VAXINIA and CHECKvacc, alongside the onCARlytics program. The onCARlytics platform is designed to enable CAR-T cells to target solid tumors by inducing the expression of CD19 on cancer cell surfaces. These programs aim to address unmet needs in oncology by providing targeted, potent, and potentially less toxic alternatives to conventional treatments.

Recent filings

Filing Released Lang Actions
Ceasing to be a substantial holder 2 pages 78.5KB
Interim / Quarterly Report Classification · 70% confidence The document text is heavily corrupted or encoded, making it difficult to extract clear content. However, the presence of repeated references to dates, fiscal periods, and structured tabular data suggests it is a substantive financial or management report rather than a brief announcement or certification. The length of the document (5134 characters) is just above the threshold for a short announcement, indicating it likely contains actual report content. There is no indication of it being a call transcript, legal proceeding, or a voting result announcement. The document does not appear to be a simple notice or a proxy solicitation. Given the structured data and references to financial periods, the best fit is an Interim / Quarterly Report (IR), which typically contains detailed financial data for a period shorter than a full fiscal year. Confidence is moderate due to the corrupted nature of the text but the length and structure support this classification. Q3 2021
2013-08-13 English
Vitamin D development program at commercialisation stage 2 pages 129.0KB
Regulatory Filings Classification · 90% confidence The document is very short (3160 characters) and contains mostly unreadable or placeholder text with no substantive financial data, regulatory references, or detailed report content. It appears to be a brief announcement about progressing a development program to commercialization stage, without detailed financial statements or analysis. There is no indication that this is a full report such as an Annual Report or Interim Report. Given the length and content, it is likely an announcement rather than a full report. The best fitting category is Regulatory Filings (RNS), which serves as a fallback for miscellaneous announcements that do not fit other categories.
2013-08-07 English
Japanese patent for novel drug delivery technology 2 pages 145.2KB
Regulatory Filings Classification · 90% confidence The document is a press release announcing the granting of a Japanese patent for Imugene's drug delivery technology. It focuses on intellectual property and commercial strategy rather than financial results, regulatory filings, or shareholder information. The content does not match any financial report, regulatory filing, or meeting-related document. It is an announcement related to patent and technology development, which does not fit into the predefined categories for financial or corporate filings. Therefore, the best fitting category is Regulatory Filings (RNS) as a general announcement that does not fit other specific categories.
2013-08-06 English
Appendix 3B - Release of shares from escrow 12 pages 303.1KB
Capital/Financing Update Classification · 100% confidence The document is titled 'Appendix 3B New issue announcement' and contains detailed information about the issuance of new securities, including the class of securities, number of securities, terms, purpose of the issue, and application for quotation on the ASX (Australian Securities Exchange). It references ASX rules and compliance, and includes sections typical of a capital raising or new share issue announcement. There is no financial performance data, earnings information, or management discussion. The document is regulatory in nature, focused on capital structure changes and securities issuance. Therefore, it fits the category of Capital/Financing Update (CAP). The document length is substantial (15,000 characters), indicating it is the announcement itself, not just a brief notice or report publication announcement.
2013-07-31 English
Appendix 4C - quarterly 5 pages 160.3KB
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Appendix 4C Quarterly report for entities admitted on the basis of commitments' and contains detailed financial data including consolidated statement of cash flows, cash flow related to operating, investing, and financing activities, payments to directors, reconciliation of cash, and compliance statements. The report covers a specific quarter ended 30th June 2013 and includes substantive financial data and analysis for that period. The length of the document (7348 characters) and the detailed financial content indicate it is a comprehensive quarterly financial report rather than a brief announcement or certification. The presence of actual financial statements and cash flow details aligns with the definition of an Interim / Quarterly Report (IR). Q4 2013
2013-07-28 English
Release of Shares from Escrow 1 page 74.9KB
Share Issue/Capital Change Classification · 95% confidence The document is an ASX announcement regarding the release of shares from escrow, specifically stating that 100,000,000 ordinary shares will be released on a certain date. This is a capital structure change related to share release, which fits the category of Share Issue/Capital Change. The document is short and focused on this specific capital event, not a full report or other type of filing.
2013-07-10 English

Browse filings by year

25 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.